Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome
Azitra Inc (AZTR)
Company Research
Source: Business Wire
BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of Netherton syndrome. The study is designed to enroll approximately 12 adult patients with twice-daily treatment for 14 days, with primary endpoints focusing on safety and tolerability, and secondary and exploratory endpoints assessing efficacy signals and biomarkers. Azitra expects to report interim safety data from the Phase 1b trial in early 2025 with full results anticipated in the second half of 2025.ATR-12 is Azitra's lead candidate, a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of an active subunit of the LEKTI protein to treat Netherton syndrome, a chronic genetic skin disease that can be life threatening."Dosing the first patient in our Phase 1b trial of ATR-12 marks a vital milestone for Azitra and for
Show less
Read more
Impact Snapshot
Event Time:
AZTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZTR alerts
High impacting Azitra Inc news events
Weekly update
A roundup of the hottest topics
AZTR
News
- Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates [Yahoo! Finance]Yahoo! Finance
- Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business UpdatesPR Newswire
- Azitra to Present at BIO-Europe 2024Business Wire
- Azitra to Participate in the 2024 Maxim Healthcare Virtual SummitBusiness Wire
- Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology CongressBusiness Wire
AZTR
Sec Filings
- 11/13/24 - Form 8-K
- 11/12/24 - Form 10-Q
- 11/6/24 - Form SC
- AZTR's page on the SEC website